Literature DB >> 1479149

A neuroendocrinological approach to evidence an impairment of central cholinergic function in aging.

E Ghigo1, S Goffi, E Arvat, E Imperiale, G M Boffano, M R Valetto, E Mazza, I Santi, A Magliona, M F Boghen.   

Abstract

A hypothalamic pathogenesis for the reduced GH secretion in aging has been reported for both animal and man. To further address this issue we studied in 31 elderly normal subjects (6 males and 25 females, aged 66-90 yr) and in 22 young healthy controls (13 males and 9 females, aged 20-35 yr) the GH responses to GHRH test (GHRH29, 1 microgram/kg i.v. as a bolus at 0 min) alone and combined with pyridostigmine, a cholinesterase inhibitor (PD, 120 mg po 60 min before GHRH), or with arginine (ARG, 30 g in 100 ml infused from 0 to 30 min). Serum IGF-I levels were lower in elderly than in young subjects (mean +/- SE: 86.9 +/- 7.2 vs 288.7 +/- 22.1 micrograms/L, p < 0.01). The GHRH-induced GH increase was lower in elderly than in young subjects (p < 0.01). PD increased the GH response to GHRH in both groups (p < 0.001), but in elderly subjects this response persisted lower (p < 0.0001) than that observed in young adults. Also ARG coadministration potentiated the GHRH-induced GH release in both groups (p < 0.0001) but in this case the elderly's responses overlapped with the young's. The GH increase observed after combined administration of ARG and GHRH was higher (p < 0.0001) than that elicited by PD plus GHRH in elderly but not in young subjects. Analyzing individual GH responses, a GH peak below the limit of normality for young adults was observed in 19 (61.3%) elderly subjects after PD plus GHRH administration while ARG plus GHRH test elicited a normal GH peak in all but one.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1479149     DOI: 10.1007/BF03345812

Source DB:  PubMed          Journal:  J Endocrinol Invest        ISSN: 0391-4097            Impact factor:   4.256


  35 in total

1.  Atropine blockade of growth hormone (GH)-releasing hormone-induced GH secretion in man is not exerted at pituitary level.

Authors:  F F Casanueva; L Villanueva; C Dieguez; J A Cabranes; Y Diaz; B Szoke; M F Scanlon; A V Schally; A Fernandez-Cruz
Journal:  J Clin Endocrinol Metab       Date:  1986-01       Impact factor: 5.958

2.  Increased pituitary response to somatostatin in aging male rats: relationship to somatostatin receptor number and affinity.

Authors:  K Spik; W E Sonntag
Journal:  Neuroendocrinology       Date:  1989-11       Impact factor: 4.914

3.  Growth hormone (GH) responsiveness to combined administration of arginine and GH-releasing hormone does not vary with age in man.

Authors:  E Ghigo; S Goffi; M Nicolosi; E Arvat; F Valente; E Mazza; M C Ghigo; F Camanni
Journal:  J Clin Endocrinol Metab       Date:  1990-12       Impact factor: 5.958

4.  Diminished pituitary responsiveness to growth hormone-releasing factor in aging male rats.

Authors:  G P Ceda; G Valenti; U Butturini; A R Hoffman
Journal:  Endocrinology       Date:  1986-05       Impact factor: 4.736

5.  Repetitive growth hormone-releasing hormone administration restores the attenuated growth hormone (GH) response to GH-releasing hormone testing in normal aging.

Authors:  M Iovino; P Monteleone; L Steardo
Journal:  J Clin Endocrinol Metab       Date:  1989-10       Impact factor: 5.958

6.  The influence of age on the 24-hour integrated concentration of growth hormone in normal individuals.

Authors:  Z Zadik; S A Chalew; R J McCarter; M Meistas; A A Kowarski
Journal:  J Clin Endocrinol Metab       Date:  1985-03       Impact factor: 5.958

7.  Effects of human growth hormone in men over 60 years old.

Authors:  D Rudman; A G Feller; H S Nagraj; G A Gergans; P Y Lalitha; A F Goldberg; R A Schlenker; L Cohn; I W Rudman; D E Mattson
Journal:  N Engl J Med       Date:  1990-07-05       Impact factor: 91.245

8.  Impaired growth hormone secretion in the adult population: relation to age and adiposity.

Authors:  D Rudman; M H Kutner; C M Rogers; M F Lubin; G A Fleming; R P Bain
Journal:  J Clin Invest       Date:  1981-05       Impact factor: 14.808

9.  The effect of age on the number of pituitary cells immunoreactive to growth hormone and prolactin.

Authors:  Y K Sun; Y P Xi; C M Fenoglio; N Pushparaj; K M O'Toole; G S Kledizik; E G Nette; D W King
Journal:  Hum Pathol       Date:  1984-02       Impact factor: 3.466

10.  Gender and age differences in the growth hormone response to pyridostigmine.

Authors:  J V Lucey; V O'Keane; K O'Flynn; A W Clare; T G Dinan
Journal:  Int Clin Psychopharmacol       Date:  1991       Impact factor: 1.659

View more
  5 in total

1.  Is the persistence of isolated GH deficiency in adulthood predicted by anatomical hypothalamic-pituitary alterations?

Authors:  S Vannelli; B Stasiowska; J Bellone; G Aimaretti; S Bellone; T Avataneo; S Cirillo; L Benso
Journal:  J Endocrinol Invest       Date:  1997-06       Impact factor: 4.256

2.  Reduction of the somatotrope responsiveness to GHRH and Hexarelin but not to arginine plus GHRH in hyperprolactinemic patients.

Authors:  S Grottoli; P Razzore; E Arvat; S E Oleandri; R Rossetto; E Ciccarelli; F Camanni; E Ghigo
Journal:  J Endocrinol Invest       Date:  1997-11       Impact factor: 4.256

3.  Impairment of growth hormone responsiveness to growth hormone releasing hormone and pyridostigmine in patients affected by Prader-Labhardt-Willi syndrome.

Authors:  L Beccaria; F Benzi; A Sanzari; L Bosio; P Brambilla; G Chiumello
Journal:  J Endocrinol Invest       Date:  1996-11       Impact factor: 4.256

4.  Low doses of either intravenously or orally administered arginine are able to enhance growth hormone response to growth hormone releasing hormone in elderly subjects.

Authors:  E Ghigo; G P Ceda; R Valcavi; S Goffi; M Zini; M Mucci; G Valenti; D Cocchi; E E Müller; F Camanni
Journal:  J Endocrinol Invest       Date:  1994-02       Impact factor: 4.256

Review 5.  Multiple Effects of Growth Hormone in the Body: Is it Really the Hormone for Growth?

Authors:  Jesús Devesa; Cristina Almengló; Pablo Devesa
Journal:  Clin Med Insights Endocrinol Diabetes       Date:  2016-10-12
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.